Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to $16.0 million.

  • Avadel Pharmaceuticals' Cash from Financing Activities was N/A to $6.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.5 million, marking a year-over-year change of. This contributed to the annual value of $16.0 million for FY2024, which is 88.20% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Cash from Financing Activities of $16.0 million as of FY2024, which was down 88.20% from $135.3 million recorded in FY2023.
  • In the past 5 years, Avadel Pharmaceuticals' Cash from Financing Activities registered a high of $179.7 million during FY2020, and its lowest value of $263,000 during FY2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $16.0 million (2024), whereas its average is $55.3 million.
  • In the last 5 years, Avadel Pharmaceuticals' Cash from Financing Activities spiked by 665,592.59% in 2020 and then crashed by 99.85% in 2021.
  • Yearly analysis of 5 years shows Avadel Pharmaceuticals' Cash from Financing Activities stood at $179.7 million in 2020, then tumbled by 99.85% to $263,000 in 2021, then spiked by 5,429.66% to $14.5 million in 2022, then surged by 830.59% to $135.3 million in 2023, then slumped by 88.20% to $16.0 million in 2024.